Exelixis Shares Soared: What You Need to Know

Before you go, we thought you'd like these...
Before you go close icon

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Exelixis (NAS: EXEL) are soaring by as much 26% today after the company announced positive preliminary results from a phase 3 clinical trial for cabozantinib.

So what: The drug is intended for patients with advanced medullary thyroid cancer, and the trial met its primary endpoint of improving progression-free survival compared with placebo. It substantially exceeded the threshold of a 75% increase in PFS assumed at the onset of the trial.

Now what: Cabozantinib significantly improved median PFS by 7.2 months relative to the placebo. Exelixis CEO Michael Morrissey called the results "an important advance for MTC patients and for Exelixis." The company will consult with the Food and Drug Administration and is hoping to begin a rolling submission of a new drug application. Exelixis hopes that the filing will be completed by the first half of 2012.

Interested in more info on Exelixis? Add it to your watchlist byclicking here.

At the time this article was published Fool contributorEvan Niuholds no position in any company mentioned.Click hereto see his holdings and a short bio. The Motley Fool owns shares of Exelixis.Motley Fool newsletter serviceshave recommended buying shares of Exelixis. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners